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Background: In patients with refractory angina who are not candidates for 
conventional revascularization, transmyocardial  laser treatment reduces 
angina significantly in the early postoperative p riod. We hypothesized that 
transmyocardial  l ser treatment damages cardiac nerve fibers that convey 
the pain of angina pectoris. Methods: Left thoracotomy was performed in 
sixteen adult mongrel dogs. Treatment groups included animals in which a 
portion of the left ventricle underwent creation of transmyocardial  chan- 
nels with a holmium:yttr ium-aluminum-garnet las r(n = 5) or chemical 
destruction of cardiac nerves by application of phenol to the epicardium 
(n = 5). Sham-operated negative control animals underwent thoracotomy 
and pericardiotomy alone (n = 6). Cardiac afferent nerve function was 
assessed by epicardial application of bradykinin, a potent algesic, before 
treatment and 2 weeks after the operation. The resulting central nervous 
system-mediated decrease in systemic mean arterial  pressure was mea- 
sured. Cardiac innervation of treated and untreated ' le f t  ventricular 
myocardium was further assessed by immunoblot analysis performed with 
an antibody against tyrosine hydroxylase, a sympathetic nerve-specific 
enzyme. Results: Before treatment, changes in systemic arterial pressure 
were seen with bradykinin stimulation in all dogs. Two weeks after 
From the Division of Cardiothoracic Surgery, Department of Sur- 
gery, aDivision of Cardiology, b and the Department ofPatholo- 
gy,C Washington University School of Medicine, St. Louis, Mo. 
Supported in part by a grant from CardioGenesis Corp., Sunny- 
vale, Calif. 
Read at the Seventy-seventh Annual Meeting of The American Asso- 
ciation for Thoracic Surgery, Washington, D.C., May 4-7, 1997. 
Received for publication May 6, 1997; revisions requested July 7, 
1997; revisions received August 12, 1997; accepted for publi- 
cation August 14, 1997. 
Address for reprints: Thoralf M. Sundt III, MD, Division of 
Cardiothoracic Surgery, Washington University School of 
Medicine, Queeny Tower, Suite 3108, One Barnes Hospital 
Plaza, St. Louis, MO 63110. 
J Thorac Cardiovasc Surg 1997;114:883-90 
Copyright © 1997 by Mosby-Year Book, Inc. 
0022-5223/97 $5.00 + 0 12/6/85535 
883 
884 Kwong et al. 
The Journal of Thoracic and 
Cardiovascular Surgery 
December 1997 
treatment, no hemodynamic response was seen after st imulation of 
laser- or phenol-treated areas, but a normal response was seen after 
st imulat ion of untreated areas in these same animals and in negative 
control animals. Immunoblots  demonstrated loss of tyrosine hydroxy- 
lase in regions of phenol and laser treatment. Conclusion: Transmyo- 
cardial laser treatment destroys cardiac nerve fibers, which may con- 
tribute to the reduced angina pectoris seen clinically. (J Thorac 
Cardiovasc Surg 1997;114:883-90) 
E arly attempts at indirect revascularization f the myocardium included Beck's pedicle procedure 1 
and Vineberg's internal thoracic artery implantation 
procedures.2, 3 With the successful development of 
cardiopulmonary bypass and the more effective 
method of direct coronary revascularization, i di- 
rect approaches were largely abandoned. Recent 
advances in laser technology, coupled with the need 
to find treatment options for an increasing number 
of patients with refractory angina who are not 
candidates for conventional ngioplasty or coronary 
artery bypass grafting, have renewed interest in 
indirect approaches to myocardial revascularization. 
Transmyocardial l ser treatment is one such indi- 
rect approach. Some have proposed that it revascu- 
larizes the myocardium by augmenting myocardial 
perfusion through laser-created channels. The pa- 
tency of these channels, however, is a topic of 
continuing controversy. Mirhoseini and Cayton 4re- 
ported the first use of transmyocardial l ser treat- 
ment in a canine model, arguing that laser energy 
would induce minimal scar tissue formation and 
result in patent endothelialized conduits for blood 
flow between the ventricular chamber and the isch- 
emic myocardium. Hardy and colleagues, s however, 
demonstrated that the common outcome of laser- 
created channels was occlusion, and that patency 
was at best a transient feature. Despite limited 
histologic analysis in patients, some investigators 
have provided support for persistent channel paten- 
cy, 6 whereas others have found evidence for early 
channel occlusion. 7-9 
A second proposed mechanism of transmyocar- 
dial laser treatment is angiogenesis, but data show- 
ing improvements in regional myocardial perfusion 
have been inconsistentJ °-13 As well, conclusive vi- 
dence for angiogenesis after transmyocardial l ser 
treatment has not been found in animal studies. 5's 
Although the exact therapeutic mechanism re- 
mains to be determined, one consistent finding from 
the clinical data has been the improvement in 
angina class rankings of patients after transmyocar- 
dial laser treatmentJ °-13 One possible explanation 
for angina relief after laser treatment is denervation 
of the myocardium. Laser-induced myocardial in- 
jury is nonspecific, and damage occurs to all tissue 
components of the myocardium, including the 
nerves that innervate the heart. Although attention 
has been focused on increased perfusion by laser 
treatment, denervation of the myocardium as a 
potential contributing factor to angina relief has not 
been examined previously. The objective of this 
study was to determine whether cardiac afferent 
fibers, which convey the pain of angina pectoris, are 
damaged by transmyocardial l ser treatment. 
Methods 
Surgical model. Adult mongrel dogs weighing approx- 
imately 25 kg were intravenously sedated with 25 mg/kg 
sodium thiopental, endotracheally intubated, ventilated, 
and maintained under general anesthesia with continu- 
ously administered 1.25% isoflurane. During the opera- 
tion and in the perioperative p riod, surface electrocar- 
diogram, oxygen saturation, and arterial blood pressure 
were monitored. Left thoracotomy and pericardiotomy 
were performed to expose the anterior left ventricle. As 
shown in Fig. 1, A, three specific anatomic regions of the 
anterior left ventricle were designated in the following 
manner: an area adjacent to the atrioventricular g oove 
(region 1), a middle area bounded by two major diagonal 
branches of the left anterior descending coronary artery 
(region 2), and the left ventricular portion of the apex of 
the heart (region 3). The temperature of the heart was 
monitored and maintained between 36 ° and 38°C by 
periodic irrigation of the thoracic avity with warm normal 
saline solution. 
Stimulation of cardiac visceral afferents by topical epi- 
cardial application of bradykinin was performed, followed 
by either laser treatment of the myocardium or applica- 
tion of phenol to the epicardium. Animals in the negative 
control (sham operation) group did not undergo this 
additional intervention. The pericardium was then loosely 
reapproximated, the thoracotomy was closed, and the 
animal was awakened from anesthesia. Another thoracot- 
omy was performed in similar fashion 2 weeks after the 
first operation, and the functional status of the cardiac 
visceral afferent fibers was again tested with bradykinin. 
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Fig. 1. Designated left ventricular myocardial regions in sham-operated (A), laser-treated (B), and 
phenol-treated (C) canine hearts. 
All dogs received humane care in accordance with the 
"Principles of Laboratory Animal Care" formulated by 
the National Society for Medical Research and the 
"Guide for the Care and Use of Laboratory Animals" 
prepared by the Institute of Laboratory Animal Resources 
and published by the National Institutes of Health (NIH 
Publication No. 85-23, revised 1985). 
Stimulation of cardiac visceral afferent nerves. Cardiac 
afferent nerves were assessed functionally by stimulation 
with topical epicardial application of bradykinin (300/xg 
in 150/~1 saline solution per stimulation) in each of the 
three designated left ventricular regions. The bradykinin 
was kept in a water bath at 36 ° C and delivered onto a I × 
1 cm gauzeplaced in the center of the myocardial region 
14 16  of interest. - Arterial blood pressure, mean arterial 
pressure (MAP), and surface electrocardiogram were 
recorded uring bradykinin stimulation. The bradykinin- 
soaked gauze was removed after 2 minutes, and the excess 
bradykinin was washed away with normal saline solution. 
Each of the three myocardial regions was stimulated again 
at the second thoracotomy. A decrease greater than 5 mm 
Hg from baseline MAP was considered to represent a
response to bradykinin stimulation. If no response to 
bradykinin stimulation was found in a particular region of 
the myocardium at the second thoracotomy, two addi- 
tional attempts were performed within the same treat- 
ment region to confirm the lack of response. Topical 
bradykinin was also applied to the exposed surface of the 
latissimus dorsi muscle, as seen in the thoracotomy oper- 
ative field, to demonstrate hat topical bradykinin was not 
diffusing into the circulation and causing the observed 
changes in blood pressure. 
Treatment groups. Region 2 of the anterior left ventri- 
cle underwent either transmyocardial laser procedure 
(n = 5), topical phenol application (n = 5), or no 
treatment (n = 6). Laser channels were created with a 
pulsed holmium:yttrium-aluminum-garnet (Ho:YAG) la- 
ser (A = 2.1 ~m; CardioGenesis Corp., Sunnyvale, Calif.). 
As shown in Fig. 1, t3, laser holes, spaced approximately 1 
cm apart, were drilled along side the diagonal vessels and 
within the bounded treatment region. Immediately after 
channel creation, hemostasis was achieved with digital 
pressure. Between 18 and 26 transmyocardial l ser chan- 
nels per heart were created in region 2 (mean number, 
22). Laser energy was delivered to the myocardium in 
bursts of 3 pulses (2 J/pulse), timed to the R wave of the 
electrocardiogram. On average, five bursts (30 J) were 
required to create a transmyocardial channel. As shown in 
Fig. 1, C, sympathetic denervation was chemically induced 
by topical application of 85% phenol to the epicardial 
surface by painting the perimeter of the treatment region 
with a cotton-tipped applicator stick. 15 The negative con- 
trol group received only sham operation. 
Immunoblotting. Changes in cardiac innervation at 2 
weeks after treatment were assessed by immunoblot anal- 
ysis of treated and untreated myocardial tissue from nine 
randomly selected animals (three from each treatment 
group) for tyrosine hydroxylase, an enzyme specific to 
sympathetic nerves. For each region of left ventricular 
myocardium sampled, approximately 500 mg frozen, un- 
fixed, full-thickness tissue was excised from the center of 
the treatment region. The tissue samples were homoge- 
nized with cold homogenization buffer (20 mmol/L 
tris(hydroxymethyl)aminomethane ydrochloride [Tris- 
HC1], 1 mmol/L ethyleneglycol-bis[/3-aminoethylether]- 
N,N,N',N'-tetraacetic a id [EGTA], 5 mmol/L sodium 
azide, 50 mmol/L sodium chloride, 10 mmol/L /3-mer- 
capto-ethanol, and phenylmethylsulfonyl 2 mmol/L fluo- 
ride, pH 7.4) and then centrifuged at 10,000 rpm for 30 
minutes at 4 ° C. Electrophoresis buffer (200 /xl; 125 
mmol/L Tris-HC1, 1 mmol/L EGTA, 2% sodium dodecyl 
sulfate, 10 mmol/L ~-mercapto-ethanol, and 2 mmol/L 
886 Kwong et al. 
The Journal of Thoracic and 
Cardiovascular Surgery 
December 1997 
250 - -  
0 m 
BP  
MAP 
150  m 
0 --  
I I I I I 
0 30  60  90  120  
T ime (seconds)  
Fig. 2. Typical blood pressure (BP) and MAP recordings during topical epicardial bradykinin stimulation 
in region 2 before treatment. 
phenylmethylsulfonyl fluoride, pH 6.8) was added to the 
supernatant and the mixture was sonicated. Equivalent 
amounts of protein from each tissue sample, as deter- 
mined by Bradford assay (Bio-Rad Chemicals, Richmond, 
Calif.), were loaded onto a 12.5% polyacrylamide gel. 
Molecular weight marker standards were also applied to 
each gel (Amersham Life Sciences, Arlington Heights, 
Ill.). 
The proteins resolved by sodium dodecyl sulfate-poly- 
acrylamide gel electrophoresis were transferred onto a 
nitrocellulose blot with a semidry transfer apparatus, and 
the accuracy of protein transfer was verified by Coomassie 
blue staining of the gel. The blots were blocked in 2% 
gelatin-phosphate buffered saline solution (PBS) over- 
night at 25 ° C. Blots were then incubated with a mouse 
monoclonal immunoglobulin G antibody monospecific for 
tyrosine hydroxylase (1:1000; Chemicon International 
Inc., Temecula, Calif.) for 3 hours at 25 ° C. After the blots 
were washed with 0.5% polyoxyethylene ether (Triton)- 
PBS, horseradish peroxidase-conjugated donkey anti- 
mouse immunoglobulin G antibody at a 1:10,000 dilution 
was applied (Jackson ImmunoResearch, West Grove, Pa.) 
and blots were incubated for 1.5 hours at 25 ° C. The blots 
were washed again with Triton-PBS, developed with the 
enhanced chemiluminescence system (Amersham Life 
Sciences), and then exposed to x-ray film. 
Data analysis. All data from bradykinin stimulation 
were reported as mean _+ standard eviation and analyzed 
with the SYSTAT system for statistics (SPSS, Inc., Chi- 
cago, Ill.). Repeated-measures analyses of variance with 
two group factors, the region of the heart and the treat- 
ment, were used to compare the percentage change in 
MAP during bradykinin stimulation before treatment and 
at 2 weeks after treatment. Contrast was used to compare 
the before-treatment response between treatment groups. 
Ap  value less than 0.05 was considered significant. 
Resu l ts  
Surg ica l  procedure.  There were no operative 
deaths, and no animals were excluded. Regional 
wall motion appeared grossly unchanged immedi- 
ately after laser treatment or phenol application. 
St imula t ion  of  card iac  pain fibers. Fig. 2 shows a 
typical blood pressure recording in response to 
bradykinin stimulation before phenol or laser treat- 
ment. In our analysis of the data, we measured the 
maximal decrease in MAP in response to bradykinin 
stimulation and represented this decrease as a per- 
centage of the baseline MAP of the animal. There 
was no difference in pretreatment response between 
treatment groups for each region (p > 0.5). Phenol 
and laser group animals responded to bradykinin 
stimulation in all left ventricular areas before phe- 
nol application or t ansmyocardial laser treatment. 
At 2 weeks after treatment, bradykinin stimulation 
in the treated left ventricular areas (region 2) of the 
phenol and laser group animals did not elicit the 
reflex response; however, untreated atrioventricular 
groove areas (region 1) in the same animals consis- 
tently showed persistence of the bradykinin-evoked 
reflex response. Region 3 of phenol- and laser- 
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Table I. Percentage of bradykinin-evoked decrease 
from baseline MAP 
Region 1 Region 2 Region 3 
Before After Before After Before After 
Sham 34_+11 31_+15 22_+9 22_+8 24_+9 23-+5 
Phenol  39_+9 32-+13 15_+6 2 -+2"  16_+15 7_+6"  
Laser 40_+10 44_+25 23_+8 0 -+0"  17_+8 11_+7" 
Values are mean -- standard eviation; MAP in mm Hg. 
*p < 0.001 (before vs after treatment). 
treated animals displayed an attenuated but variable 
response to bradykinin stimulation. The negative 
control group consistently showed responses to bra- 
dykinin stimulation in all left ventricular egions. 
Topical application f bradykinin to the surface of 
the latissimus dorsi muscle did not produce any 
hemodynamic changes (data not shown). Table I 
summarizes the bradykinin-evoked response data 
from the three treatment groups in numeric format. 
Heart rate did not appear to be affected by transient 
application of bradykinin. 
Immunoblotting. Fig. 3 shows a representative 
immunoblot. A 62 kd band, corresponding to the 
presence of tyrosine hydroxylase, 17'18 was identified 
in the untreated tissue (region 1) in both the phenol 
and laser groups. In contrast, it was significantly 
attenuated in phenol-treated myocardium and en- 
tirely absent in laser-treated myocardium. The 62 kd 
band was present in tissues from regions 1, 2, and 3 
in all negative control animals. All animals in a 
particular treatment group produced the same pat- 
tern of tyrosine hydroxytase immunoreactivity in 
regions 1 and 2 of the left ventricular myocardium. 
A 62 kd band was variably present in region 3 of 
phenol and laser group animals. 
Discussion 
In this study, we demonstrated in a canine model 
that a neural-specific enzyme, as well as the function 
of cardiac nerves on the end-organ level, is lost as a 
result of transmyocardial l ser treatment. Clinical 
studies have shown that most patients have a signif- 
icant decrease in angina after undergoing transmyo- 
cardial laser treatment. 11-13 Our data implicate de- 
nervation as one possible mechanism for this angina 
relief. 
Cardiac innervation i  the canine model has been 
extensively investigated 19'2° and roughly parallels 
that found anatomically in humans. In the dog, 
cardiac sympathetic efferent nerves traverse the 
subepicardial portion of the myocardium, giving off 
66kD- -  
46kD- -  
Sham Phenol  Laser 
1 2 3 1 2 3 1 2 3 
Fig. 3. Representative immunoblot showing loss of ty- 
rosine hydroxylase in treated myocardium (region 2) of 
phenol- and laser-treated animals. Persistence of tyrosine 
hydroxylase inregion 3 of the laser-treated animal reflects 
anterior and posterior contributions to the innervation i
the cardiac apex. Numbers correspond to reatment re- 
gions of the heart depicted in Fig. 1. 
deeper branches that extend towards the subendo- 
cardium. Cardiac visceral afferent nerve fibers, 
which convey the pain of angina, are thought to 
travel alongside the cardiac sympathetic efferents en 
route to the central nervous sy temY 
The algesic property of bradykinin and the anat- 
omy of the nerves innervating the heart provide a 
means of assessing the presence of functional affer- 
ent pain fibers. Topically applied bradykinin stimu- 
lates subepicardial visceral afferents~4; the resulting 
bradykinin-evoked cardiovascular response, which 
was measured in our study, is a result of central 
nervous ystem integration of the pain stimulus. The 
characteristic biphasic reflex response to bradykinin 
stimulation consists of an initial decrease in MAP 
from baseline followed by a late, albeit less consis- 
tently seen, hypertensive r sponseJ 4 Other investi- 
gators have found this late response to be variable 
from animal to animal and to be affected by the level 
of anesthesiaJ 5 We did not reproducibly observe 
this component, possibly because of a relatively 
deep anesthetic plane. 
Although it is possible that bradykinin may interact 
directly with the myocardium, bradykinin receptors 
have been definitively identified only on vascular 
smooth muscle cells, fibroblasts, endothelial cells, and 
neural-derived cells. 22 Support for the presence of 
bradykinin receptors has been shown indirectly in 
neonatal rat cardiac myocyte cell cultures, 22 but in situ 
histologic and morphologic characterizations of brady- 
kinin receptors in the heart are still lacking. In our use 
of bradykinin, and in that of others, 15' 16 only a limited 
total area of myocardium is briefly exposed to the 
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chemical. No significant gross changes in myocardial 
contraction were observed after this application of 
bradykinin to the heart. The hemodynamic changes we 
observed with bradykinin application to the epicar- 
dium, which have also been seen by others, are likely 
the result of cardiac visceral afferent nerve stimulation 
by bradykinin. 
Our positive control animals were treated with 
topical phenol application, because this has been used 
previously to denervate the myocardium. 15'16 After 
topical application of phenol, the reflex hemodynamic 
response to bradykinin stimulation was lost in the 
treated areas. In our study, laser-treated myocardium 
was similarly unresponsive to bradykinin stimulation, 
suggesting that denervation had occurred as a result of 
transmyocardial laser treatment. 
In addition to loss of cardiac nerve function, our 
immunoblot data show that neural-specific elements 
were also lost as a result of transmyocardial l ser 
treatment. Tyrosine hydroxylase is a sympathetic 
efferent nerve enzyme involved in the rate-limiting 
step in the biosynthesis of norepinephrine from 
tyrosine. 23 Immunoblot analysis with an antibody 
monospecific for tyrosine hydroxylase yields a 62 kd 
protein band. 17' 18 Our immunoblots demonstrate 
an absence of this neuronally derived protein in 
laser-treated myocardium. One explanation for this 
finding is that cardiac nerves are damaged or de- 
stroyed as a result of transmyocardial l ser treat- 
ment, and that the concentration f tyrosine hydrox- 
ylase in treated myocardium is diminished in 
consequence. It seems unlikely that tyrosine hydrox- 
ylase, a critical enzyme of functional sympathetic 
neurons, should be destroyed in isolation as a result 
of laser injury while sparing the integrity of the 
neuron itself. 
It is noteworthy that the magnitude ofresponse to 
bradykinin stimulation i the unaltered canine heart 
was maximal in the ventricular base (region 1) and 
decreased inthe apex (region 3). Because the nerves 
innervating the heart ypically travel from a basal to 
apical direction as they course through the myocar- 
dium, their anatomic distribution results in differ- 
ences in neural density among the different regions 
of the left ventricle. 
Although consistent changes as a result o phenol 
or laser treatment were seen in region 2, region 3 of 
these animals demonstrated variability in both bra- 
dykinin-evoked response and tyrosine hydroxylase 
immunoreactivity. This variability is perhaps a re- 
flection of the dual innervation that the apex (region 
3) derives from neural plexuses from both the 
anterior and posterior egions of the heart. Conse- 
quently, the apical region exhibits more variability in 
indexes representative of innervation. In particular, 
as shown in Fig. 3, immunoblot analysis of the 
laser-treated animal demonstrated complete ab- 
sence of tyrosine hydroxylase in region 2 but a 
persistence ofthe enzyme in region 3. This finding is 
consistent with an overlap of innervation that can 
occur in the cardiac apex. 
The precise mechanism by which a series of laser 
channels in myocardium creates regional denerva- 
tion remains unknown. The laser produces a focused 
delivery of light energy, but the injury it causes in 
living tissues is not limited only to the formed 
channel. Hardy and associates 5 described histologic 
zones of injury emanating outward from a central 
zone of vaporization. Extension of thermal injury 
beyond the site of direct injury has been detected in 
normal-appearing cardiomyocytes by observing the 
loss of naturally occurring birefringence from these 
cells under polarized light microscopy. 24Because 
laser energy is dissipated mostly as heat, a small 
degree of subtle thermal damage, undetectable by
routine light microscopy, may be occurring in the 
myocardium adjacent to laser-created channels. 
Thus the combined tissue destruction and nearby 
tissue thermal injury from a laser channel may act to 
interrupt nerves as they course through the myocar- 
dium. In our study, we created laser channels 1cm 
apart to parallel the procedure that is currently 
performed in patients. 1°-13 
The results of our study are compatible with 
denervation of the laser-treated myocardium as a 
result of interruption of myocardial neural net- 
works. It follows that the density of laser channels, 
and also possibly the depth of these channels, in the 
myocardial wall may determine the ultimate xtent 
of denervation resulting from this procedure. 
The role of transmyocardial laser treatment in the 
management of patients with ischemic heart disease 
continues to evolve. Our data suggest that myocar- 
dial denervation asa consequence of laser treatment 
may contribute to the angina relief that is observed 
clinically. Although this study in no way rules out 
concomitant augmented perfusion by any of a vari- 
ety of mechanisms, it does emphasize the impor- 
tance of distinguishing clinical angina relief from 
augmented perfusion and cautions against mistaking 
improvement in one for evidence of the other. The 
potential for creating silent ischemia must be con- 
sidered when evaluating the utility of this therapeu- 
tic modality. 
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Discuss ion 
Dr. Lawrence H. Cohn (Boston, Mass.). Dr. Buckberg, 
who was originally scheduled to do this discussion, could 
not be here and asked me to substitute for him, and I'm 
happy to do so. 
Dr. Kwong, I think your experimental hypothesis was 
brilliant, and I think your experiments were beautifully 
carried out. Unfortunately, I disagree with your conclusion. 
At the Brigham, we believe because of both clinical and 
now some long-term chronic ischemic laboratory studies 
that angiogenesis, not denervation, is the primary mech- 
anism by which this new therapy works. You heard in the 
previous research presented that increase in perfusion 
measured by scans across time can be documented by 
reduction in ischemic segments, and we now have some 
patients for whom follow-up has lasted longer than 3 years 
in whom this effect this has persisted. 
We've now seen this in a laboratory experiment, done in 
a 6-month swine model chronic of ischemia. Dr. Ross 
Reul in our lab has shown significant increases in suben- 
docardial blood flow. 
In a 6-month postischemic laser model in the swine, 
there is a perfusion of subendocardial blood vessels, both 
small and medium-sized muscular arteries. These were 
compared with normal control preparations read blindly 
by pathologists and were significantly increased above 
control values. I wonder whether you could comment on 
this observation. 
It's also well known that different lasers cause different 
amounts of tissue damage, and I think it's well known that 
the Ho:YAG laser does have a substantially increased 
local tissue injury compared with the carbon dioxide laser 
used in this and our clinical study. I wonder whether you 
could comment as to whether that may have been the 
reason that you got some of your data. 
Finally, Dr. Buckberg suggested to me that your theory 
of mechanism ay well be the reason why a lot of these 
patients who are have terrible symptoms how an imme- 
diate cessation in angina that really is quite dramatic in 
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many instances. Actually, if long lasting, this would be 
quite a dangerous theory because itwould be like painless 
ischemia; as people did more exercise in the later postop- 
erative period, this could be actually a dangerous therapy 
if your theory were to hold true. I wonder whether you 
could comment on that as well. 
Dr. Craig R. Smith (New York, N.Y.). Practically every 
time I speak about ransmyocardial laser treatment, some- 
one asks whether the beneficial effect could be explained 
by denervation. I've always acknowledged that possibility 
but haven't known how to answer the question. You are to 
be congratulated for making a step toward answering this 
important question. 
Just a couple of things I'll comment on. One is that our 
group at Columbia will soon present and publish a similar 
study confirming these results. We didn't include a phenol 
control group, which is a nice feature of your study. We 
are currently looking at some other ways of producing this 
same effect, which may come around to answering the 
question Dr. Cohn just raised about whether this is an 
effect specific to the Ho:YAG laser. 
If we think about other implications of these findings, 
though, it becomes a little more complicated. How does 
this differ conceptually from many other things we do? 
Look at the effect of phenol, for example. I presume 
phenol acts on the surface, implying that the nerves are on 
the surface. How does this differ from taking down a lot of 
epicardial adhesions in a reoperation, using cautery to 
control epicardial bleeding, placing multiple pacing wires, 
applying topical hypothermia, nd things of that sort that 
we do in the normal conduct of heart surgery? Do you 
suppose that these could also produce denervation? 
Dr. Kwong. ! thank both Dr. Cohn and Dr. Smith for 
their insightful remarks and questions. Let me take Dr. 
Cohn's points first. 
Dr. Cohn mentioned that there are considerable data to 
suggest hat increased regional perfusion occurs in the 
area of myocardium that has been lased. Although I do 
not doubt that, our study is principally directed toward 
looking at the process of the destruction of cardiac nerves 
and denervation asone contributing mechanism in angina 
relief. So our study does not exclude other mechanisms 
that may coexist as a result of the transmyocardial l ser 
treatment. 
Regarding Dr. Cohn's second question, in terms of the 
varying laser-tissue interactions that may occur as a result 
of different lasers, I can only speak to the Ho:YAG laser 
with which our experiments were performed. I do not 
have any data regarding the carbon dioxide laser, and 
although one could expect hat different laser parameters 
might cause different degrees of laser-tissue interaction, I 
cannot comment knowledgeably on that. 
With respect to Dr. Cohn's third point, regarding 
painless ischemia, I think the jury is still out on that. As 
Dr. Cohn has mentioned, there seems to be evidence from 
some investigators that angiogenesis may be another 
mechanism of this transmyocardial l ser procedure. But 
what our data would seem to imply is that the immediate, 
dramatic angina relief that patients have after this proce- 
dure may be somehow mediated by the destruction of the 
afferent nerves, the A8 fibers and C fibers that carry the 
pain sensation of angina. 
Dr. Smith, you mentioned that other methods that 
cardiac surgeons employ may also cause denervation, and 
I think that's an astute point. In fact, this is not a new 
topic. Dr. Dwight Harken, in a 1955 article in Circulation, 
wrote on deepicardialization with 95% phenol in a dog 
model and also reported in that same article on a small 
series of patients in whom there was rapid relief of angina 
after phenol treatment, but the mortality in follow-up 
appeared to be unchanged. Drs. Paul Ebert and David 
Sabiston also commented on some of the results with 
surgical denervation in an ischemic dog model that 
showed a reduction in ventricular arrhythmias in the 
surgically denervated animals. 
It's tempting to speculate, as did Drs. Ebert and 
Sabiston in their 1968 article in theAnnals of Surgery, that 
perhaps a localized sympathectomy ay be occurring as a 
result of denervation. Perhaps some of these flow data 
that we are seeing in the clinical setting may be related to 
this. Although our study does not directly address this 
issue, it is possible that other mechanisms may coexist with 
denervation asa result of transmyocardial laser treatment. 
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